BOSTON, July 15 /PRNewswire/ --Scimitar Equity, LLC issues a review of Advaxis, Inc (OTC Bulletin Board: ADXS), entitled, "The New Generation of Cancer Immunotherapeutics".
This review is available at website: http://www.scimitarequity.com.
Based in North Brunswick, New Jersey, Advaxis, Inc is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets HPV-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The Lm platform also has applications in the fields of infectious disease and autoimmune disorders. For further information, please visit: http://www.advaxis.com .
Scimitar Equity, LLC provides sponsored equity research of emerging
healthcare companies for the investing communities. We certify that all the
views expressed in this review, accurately reflect our personal views about
Advaxis, Inc (OTCBB: ADXS) and its or their securities. No part of our
compensation was, is, or will be, directly or indirectly, related to the
specific recommendations or views contained in this review and we will not
have any investment banking relationships or personal investment in any
sponsored company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed as an
offer to sell or the solicitation of an offer to buy. Scimitar was paid for
preparing this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the information
contained herein is based on sources that we believe to be reliable but is
not guaranteed by us as being accurate and does not purport to be a
complete statement or summary of the available data. Any opinions expressed
are statements of our own judgment as of the date of publication and are
subject to change without notice. Please read all our important
Scimitar Equity, LLC
Henry W. McCusker
Director of Research
phone: (617) 559.1080
|SOURCE Scimitar Equity, LLC|
Copyright©2008 PR Newswire.
All rights reserved